<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045264</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-FIR-101</org_study_id>
    <nct_id>NCT02045264</nct_id>
  </id_info>
  <brief_title>Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers</brief_title>
  <official_title>An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of
      icatibant administered to adult Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE),
      an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema
      of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE
      attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by
      asphyxiation if undiagnosed and/or untreated.

      Icatibant has been approved in over 40 countries around the world including the United States
      (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults.
      This study is being conducted to evaluate the safety and tolerability of icatibant in a
      Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of
      icatibant after single subcutaneous injection.

      This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in
      order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will
      receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1
      site in the US. The study will consist of a Screening Period, a Treatment Period, and a
      Follow-Up Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Icatibant and Metabolites</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CL/F) of Icatibant</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>The rate at which a drug is removed from the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
    <description>AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Treatment-Emergent Adverse Events</measure>
    <time_frame>TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With Any Injection Site Reactions.</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Over 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Icatibant (30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icatibant (30 mg)</intervention_name>
    <description>On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments</description>
    <arm_group_label>Icatibant (30 mg)</arm_group_label>
    <other_name>Firazyr</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status
             defined as absence of clinically significant findings in medical history or screening
             assessments

          2. Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years,
             and having Japanese parents and Japanese maternal and paternal grandparents

          3. Body mass index of 18 to 28 kg/m2, inclusive

        Exclusion Criteria:

          1. History of, or current, clinically significant disease and/or abnormalities

          2. Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of
             Day 1 or inability to refrain from smoking during the study confinement period

          3. Subject has current abnormal thyroid function, as defined as abnormal screening
             thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable
             dose of thyroid medication for at least 12 weeks is permitted

          4. History of drug allergy or other allergy that, in the opinion of the investigator,
             contraindicates participation

          5. Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
             Female subjects who consume more than 14 units of alcohol per week or 2 units per day.
             (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or =0.75oz
             alcohol)

          6. Routine consumption of more than 2 units of caffeine per day or subjects who
             experience caffeine withdrawal headaches. (1 caffeine unit is contained in the
             following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one
             12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola
             are not considered to contain caffeine)

          7. Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations) with the exception of female hormonal replacement therapy or hormonal
             contraceptives. Occasional use of over-the-counter doses of ibuprofen or acetaminophen
             for minor self-limited pain (eg, headaches) is also acceptable. Current use is defined
             as use within 7 days of the first dose of investigational product\

          8. Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Kimura, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <results_first_submitted>January 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Firazyr</keyword>
  <keyword>Angioedema</keyword>
  <keyword>Angioedemas, Hereditary</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Urticaria</keyword>
  <keyword>Skin Diseases, Vascular</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Hypersensitivity, Immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Icatibant</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Analgesics, Non-Narcotic</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Sensory System Agents</keyword>
  <keyword>Peripheral Nervous System Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Adrenergic Antagonists</keyword>
  <keyword>Adrenergic Agents</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Icatibant</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Peripheral Nervous System Agents</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Icatibant (30 mg)</title>
          <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
      <group_list>
        <group group_id="B1">
          <title>Icatibant (30 mg)</title>
          <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of Icatibant and Metabolites</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Icatibant and Metabolites</title>
          <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Icatibant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" spread="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340" spread="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365" spread="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites</title>
        <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites</title>
          <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Icatibant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites</title>
        <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites</title>
          <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Icatibant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites</title>
        <description>AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites</title>
          <description>AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Icatibant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2320" spread="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1750" spread="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1960" spread="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CL/F) of Icatibant</title>
        <description>The rate at which a drug is removed from the body.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL/F) of Icatibant</title>
          <description>The rate at which a drug is removed from the body.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13200" spread="1890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Treatment-Emergent Adverse Events</title>
        <description>Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.</description>
        <time_frame>TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Treatment-Emergent Adverse Events</title>
          <description>Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.</description>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>Treatment Emergent Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With Any Injection Site Reactions.</title>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Any Injection Site Reactions.</title>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cutaneous pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching/Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results</title>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results</title>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.75 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites</title>
        <description>AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites</title>
          <description>AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>The Pharmacokinetic Set consisted of all subjects who had taken the single dose of icatibant and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Icatibant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2320" spread="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1740" spread="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1950" spread="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure</title>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure</title>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure</title>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure</title>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="17.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <time_frame>Over 48 hours post-dose</time_frame>
        <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
        <group_list>
          <group group_id="O1">
            <title>Icatibant (30 mg)</title>
            <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <population>The Safety Set consisted of all subjects who had taken the single dose of icatibant.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.5 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Icatibant (30 mg)</title>
          <description>Subjects received a 30mg dose of icatibant administered as a single subcutaneous injection in the abdominal area on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

